Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.50 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | IL18 | Q14116 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037209 | 0.82 | PAX8 (0.46) | ALDH1A1PAX8MAPTSMN1; SMN2RAB9A | |
| SCHEMBL13841454 | 0.80 | ALDH1A1 (0.73) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL14075485 | 0.80 | ALDH1A1 (0.73) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11260465 | 0.80 | MAPT (0.57) | ALDH1A1PAX8MAPTRAB9AKMT2A | |
| SCHEMBL20941638 | 0.79 | SAE1 (0.62) | ALDH1A1PAX8MAPTRAB9AKMT2A | |
| SCHEMBL20941640 | 0.79 | KDM1A (0.61) | ALDH1A1PAX8MAPTSMN1; SMN2RAB9A | |
| SCHEMBL10238819 | 0.79 | ALDH1A1 (0.71) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16569387 | 0.79 | ALDH1A1 (0.71) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6607271 | 0.79 | ALDH1A1 (0.71) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4594156 | 0.78 | SMN1; SMN2 (0.74) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| EP-2590953-B1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-10-29 | — | — | EP | disclosed |
| EP-2590953-B1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| EP-2590953-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004604-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | ALDH1A1 2584/4885PAX8 4385/4885MAPT 584/4885 |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | ALDH1A1 2584/4885PAX8 4385/4885MAPT 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.